Century Therapeutics (IPSC) Non-Current Debt (2020 - 2022)

Century Therapeutics (IPSC) has 3 years of Non-Current Debt data on file, last reported at $3.7 million in Q4 2022.

• Non-Current Debt for Q4 2022 came in at $3.7 million, down 58.0% year-over-year; the trailing twelve-month figure through Dec 2022 was $3.7 million (down 58.0% YoY), and the FY2022 annual result was $3.7 million, down 58.0% from the prior year.
• Non-Current Debt retreated to $3.7 million in Q4 2022 per IPSC's latest filing, from $6.1 million in the prior quarter.
• Over five years, Non-Current Debt peaked at $10.0 million in Q1 2022 and troughed at $3.7 million in Q4 2022.
• A 3-year average of $7.8 million and a median of $8.7 million in 2021 frame the typical range for Non-Current Debt.
• The sharpest annual moves came in 2021 and 2022: Non-Current Debt dropped 7.61% in 2021, then sank 58.0% in 2022.
• A 3-year view of Non-Current Debt shows it stood at $9.6 million in 2020, then fell by 7.61% to $8.9 million in 2021, then slumped by 58.0% to $3.7 million in 2022.
• Business Quant data shows IPSC's Non-Current Debt at $3.7 million in Q4 2022, $6.1 million in Q3 2022, and $8.5 million in Q2 2022.